ストックスクリーナーアプリを入手
6.28
2.64%
-0.17
アフターアワーズ：
6.30
0.02
+0.32%
Aura Biosciences Inc (AURA) 最新ニュース
Aura Biosciences (AURA) director awarded 15,000 RSUs and 30,000 options - Stock Titan
Aura Biosciences (NASDAQ: AURA) director receives RSUs and 30,000 stock options - Stock Titan
Aura Biosciences (AURA) director receives RSUs and stock options - Stock Titan
Aura Biosciences (AURA) awards director RSUs and $6.21 stock options - Stock Titan
Technical Reactions to AURA Trends in Macro Strategies - Stock Traders Daily
Aura Biosciences (AURA) Gains 3% as Shares Bounce from SupportNHNL Ratio - newsline.com
Aura Biosciences, Inc. 8-K Filing Details for June 11, 2026: Emerging Growth Status and Shareholder Vote Submission 1821 – Minichart - Minichart
InvestingPro’s Fair Value spotted Aura Biosciences’ 47% decline By Investing.com - Investing.com
Aura Biosciences Announces Results of 2026 Annual Meeting - TipRanks
Shareholders back Aura Biosciences (NASDAQ: AURA) directors and auditor - Stock Titan
Aura Biosciences Inc. Q1 2026 Earnings: Wider-than-Expected Loss Marks Early-Stage Pipeline Progress - newsline.com
Aura Biosciences gears up for Bel-Sar filing as pivotal eye cancer trial advances - MSN
Trading the Move, Not the Narrative: (AURA) Edition - Stock Traders Daily
Aura Biosciences highlights Bel-Sar eye cancer strategy, mid-year bladder data - MSN
Aura Biosciences completes phase 3 enrollment for eye cancer drug By Investing.com - Investing.com India
AURA Technical Analysis & Stock Price Forecast - Intellectia AI
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma - The Manila Times
Aura Biosciences completes enrollment in Phase 3 trial for early choroidal melanoma treatment - Pluang
Aura Biosciences completes phase 3 enrollment for eye cancer drug - Investing.com
Eye cancer trial hits 108 patients as Aura tests new frontline therapy - Stock Titan
AURA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelinePost-Announcement Reaction - The Legal Advocate
AURA News | AURA BIOSCIENCES INC (NASDAQ:AURA) - ChartMill
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances - TradingView
AURA: Bel-sar leads innovation in ocular oncology with robust data and a strong financial runway - TradingView
H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Ken Fisher's Aura Biosciences Inc(AURA) Holding History - GuruFocus
(AURA) Volatility Zones as Tactical Triggers - Stock Traders Daily
AURA Q1 2026 Earnings: EPS Misses Estimates, Stock Rises 2.4% on Pre-Clinical ProgressBalance Sheet Strength - Newser
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AURA Director Holles Acquires 2.17M Stock Options on May 20, 2026 - Meyka
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data - inkl
Aura Biosciences grants inducement equity awards to new CEO Natalie Holles under Nasdaq rules. - Pluang
Aura Biosciences Grants Inducement Equity Awards to New CEO Natalie Holles - Quiver Quantitative
Large equity awards granted to Aura Biosciences (AURA) director Natalie Holles - Stock Titan
New Aura Biosciences CEO awarded options on 2.17M shares at $7.39 - Stock Titan
AURA: Bel-sar shows promise for vision-preserving cancer therapy, with pivotal data expected soon - TradingView
Wall Street analysts predict a 201.49% upside in Aura Biosciences (AURA): Here's what you should know - MSN
LifeSci Capital Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
TradingKey - TradingKey
AURA Stock Price and Chart — NASDAQ:AURA - TradingView
Chen Yu and TCG Crossover report combined 9.9% stake in Aura Biosciences (AURA) - Stock Titan
Aura Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Leerink Partners Maintains Aura Biosciences(AURA.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights - The Manila Times
Major Investor Makes Dramatic Exit from Aura Biosciences - TipRanks
Aura Biosciences reports Q1 results, appoints new CEO - TipRanks
Aura Biosciences (NASDAQ: AURA) posts higher Q1 loss but extends cash runway - Stock Titan
Matrix Capital fund exits 6.9M Aura Biosciences (AURA) shares in open-market sale - Stock Titan
Matrix Capital exits Aura Biosciences (AURA) after 6.9M-share, $5.64 repurchase - Stock Titan
Aura Biosciences Q1 net loss widens on higher R&D costs - TradingView
Aura Biosciences 1Q Loss/Shr 50c >AURA - Moomoo
Aura Biosciences (NASDAQ: AURA) details $299M raise, cash runway and Phase 3 plans - Stock Titan
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):